



PRESS RELEASE  
STOCKHOLM, DECEMBER 3, 2020

THIS PRESS RELEASE MAY NOT BE MADE PUBLIC, PUBLISHED OR DISTRIBUTED, DIRECTLY OR INDIRECTLY, IN OR INTO AUSTRALIA, HONG KONG, JAPAN, CANADA, NEW ZEALAND, SWITZERLAND, SINGAPORE, SOUTH AFRICA, THE UNITED STATES OR ANY OTHER JURISDICTION IN WHICH SUCH ACTIONS, WHOLLY OR IN PART, WOULD BE SUBJECT TO LEGAL RESTRICTIONS. THIS PRESS RELEASE DOES NOT CONSTITUTE AN OFFER TO BUY SECURITIES IN MOBERG PHARMA AB (PUBL). SEE ALSO THE SECTION "IMPORTANT INFORMATION" BELOW IN THIS DOCUMENT.

## Moberg Pharma publishes prospectus relating to the rights issue

Moberg Pharma AB (publ) (OMX: MOB) ("Moberg Pharma" or the "Company") announces that the prospectus relating to the Company's fully guaranteed rights issue of units consisting of ordinary shares and warrants (the "Rights Issue") has been approved and registered by the Swedish Financial Supervisory Authority and is available on the Company's website [www.mobergpharma.se/investerare/prospekt](http://www.mobergpharma.se/investerare/prospekt) and will also be available at the Swedish Financial Supervisory Authority's website [www.fi.se](http://www.fi.se).

The prospectus can be ordered from Moberg Pharma by e-mail: [info@mobergpharma.se](mailto:info@mobergpharma.se) subject to certain legal restrictions. The prospectus will also be available on the Company's website [www.mobergpharma.com/investors/prospectus](http://www.mobergpharma.com/investors/prospectus), and at the Swedish Financial Supervisory Authority's, website [www.fi.se](http://www.fi.se). Additional information related to the Rights Issue is also available on the Company's website.

### Timetable for the Rights Issue

|                  |   |
|------------------|---|
| 3 December 2020  | Record date for the right to subscribe for Units with support of units rights |
| 7 December 2020  | Subscription period commences   |
| 7 December 2020  | Trading in unit subscription rights commences                                 |
| 7 December 2020  | Trading in paid subscribed unit ("BTU") commences                             |
| 17 December 2020 | Trading in unit subscription rights ends                                      |
| 21 December 2020 | Subscription period ends  |
| 14 January 2021  | Trading in BTU ends   |
| 20 January 2021  | Trading in new ordinary shares and warrants commences                         |

### Advisors

Vator Securities is the financial advisor and Gernandt & Danielsson Advokatbyrå is the legal advisor to Moberg Pharma in connection with the Rights Issue.

### For additional information, please contact:

Anna Ljung, CEO, telephone: +46 707 66 60 30, e-mail: [anna.ljung@mobergpharma.se](mailto:anna.ljung@mobergpharma.se)

Mark Beveridge, VP Finance, telephone: +46 76 805 82 88, e-mail: [mark.beveridge@mobergpharma.se](mailto:mark.beveridge@mobergpharma.se)

### About this information

The information was submitted for publication, through the agency of the contact persons set out above, at 12.30 a.m. CET on December 3, 2020.



**About Moberg Pharma, [www.mobergpharma.com](http://www.mobergpharma.com)**

Moberg Pharma AB (publ) is a Swedish pharmaceutical company focused on commercializing proprietary innovations based on drug delivery of proven compounds. The company's main asset, MOB-015, is a novel topical treatment for onychomycosis, with recently completed phase 3 trials in more than 800 patients. The pipeline also includes the late-stage asset BUPI for pain relief in oral mucositis, intended to be spun off in the separate company OncoZenge. Clinical data generated for both assets indicate they have the potential to become market leaders in their respective niches. Moberg Pharma is headquartered in Stockholm and the company's shares are listed on the Small Cap list of Nasdaq Stockholm (OMX: MOB).

**IMPORTANT INFORMATION**

Publication, release or distribution of this press release may in certain jurisdictions be subject to legal restrictions and persons in the jurisdictions where this press release has been made public or distributed should be informed of and follow such legal restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with applicable rules in each jurisdiction. This press release does not constitute an offer or solicitation to buy or subscribe for any securities in Moberg Pharma in any jurisdiction, either from Moberg Pharma or from anyone else.

This press release is not a prospectus according to the definition in Regulation (EU) 2017/1129 (the "**Prospectus Regulation**") and has not been approved by any regulatory authority in any jurisdiction. Any purchase of securities of Moberg Pharma in the Rights Issue should only be made on the basis of the information contained in the formal prospectus issued in connection with the Rights Issue, which was approved the Swedish Financial Supervisory Authority on December 3, 2020.

This press release does not constitute an offer or solicitation to buy or subscribe for securities in the United States. The securities mentioned herein may not be sold in the United States without registration, or without an exemption from registration, under the U.S. Securities Act from 1933 ("**Securities Act**"), and may not be offered or sold within the United States without being registered, covered by an exemption from, or part of a transaction that is not subject to the registration requirements according to the Securities Act. There is no intention to register any securities mentioned herein in the United States or to issue a public offering of such securities in the United States. The information in this press release may not be released, published, copied, reproduced or distributed, directly or indirectly, wholly or in part, in or to Australia, Hong Kong, Japan, Canada, New Zealand, Switzerland, Singapore, South Africa, the United States or any other jurisdiction where the release, publication or distribution of this information would violate current rules or where such an action is subject to legal restrictions or would require additional registration or other measures beyond those that follow from Swedish law. Actions in contravention of this instruction may constitute a violation of applicable securities legislation.

Offers to the public are permitted in Sweden and Denmark from and including the date of approval of the prospectus by the competent authority in Sweden and the competent authority in Denmark has been notified in accordance with the Prospectus Regulation ("Prospectus Publication"), through to and including the settlement date.

Elsewhere in the EEA, and in advance of Prospectus Publication, this announcement and this offering are only addressed to and directed at persons in Member States of the EEA, who are "Qualified Investors" within the meaning of Article 2(1)(e) of the Prospectus Regulation. The securities are only available to, and any invitation, offer or agreement to subscribe, purchase or otherwise acquire such securities will be engaged in only with Qualified Investors. This announcement should not be acted upon or relied upon in any member state of the EEA by persons who are not Qualified Investors.

**Forward-looking statements**

This press release contains forward-looking statements related to the Company's intentions, estimates or expectations with regard to the Company's future results, financial position, liquidity, development, outlook, estimated growth, strategies and opportunities as well as the markets in which the Company is active. Forward-looking statements are statements that do not refer to historical facts and can be identified by the use of terms such as "believes," "expects," "anticipates," "intends," "estimates," "will," "may," "implies," "should," "could" and, in each case, their negative, or comparable terminology. The forward-looking statements in this press release are based on various assumptions, which in several cases are based on further assumptions. Although the Company believes that the assumptions reflected in these forward-looking statements are reasonable, there is no guarantee that they will occur or that they are correct. Since these assumptions are based on



assumptions or estimates and involve risks and uncertainties, actual results or outcomes, for many different reasons, may differ materially from those what is stated in the forward-looking statements. Due to such risks, uncertainties, eventualities and other significant factors, actual events may differ materially from the expectations that expressly or implicitly are contained in this press release through the forward-looking statements. The Company does not guarantee that the assumptions which serve as a basis for the forward-looking statements in this press release are correct, and each reader of the press release should not rely on the forward-looking statements in this press release. The information, opinions and forward-looking statements that expressly or implicitly are stated herein are provided only as of the date of this press release and may change. Neither the Company nor any other party will review, update, confirm or publicly announce any revision of any forward-looking statement to reflect events that occur or circumstances that arise with respect to the contents of this press release, beyond what is required by law or Nasdaq Stockholm's rules for issuers.